Literature DB >> 29052601

Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis.

Jean-Baptiste Gibier1, Viviane Gnemmi1, François Glowacki2, Eileen M Boyle3, Benjamin Lopez4, Evelyne MacNamara5, Maxime Hoffmann6, Raymond Azar7, Thomas Guincestre8, Franck Bourdon9, Marie-Christine Copin1, David Buob10.   

Abstract

Light chain cast nephropathy is the most common form of kidney disease in patients with multiple myeloma. Light chain casts may occasionally show amyloid staining properties, that is, green birefringence after Congo red staining. The frequency and clinical significance of this intratubular amyloid are poorly understood. Here, we retrospectively assessed the clinicopathological features of 60 patients with histologically proven light chain cast nephropathy with a specific emphasis on intratubular amyloid, especially, its association with extrarenal systemic light chain amyloidosis. We found intratubular amyloid in 17 cases (17/60, 28%) and it was more frequent in patients with λ light chain gammopathy (13/17 in the 'intratubular amyloid' group vs 19/43 in the 'no intratubular amyloid' group, P=0.02). Pathological examination of extrarenal specimens showed that intratubular amyloid was significantly associated with the occurrence of systemic light chain amyloidosis (5/13 in the 'intratubular amyloid' group vs 0/30 in the 'no intratubular amyloid' group, P=0.001). Our results indicate that first, intratubular amyloid is not a rare finding in kidney biopsies of patients with light chain cast nephropathy, and, second, it reflects an amyloidogenic capacity of light chains that can manifest as systemic light chain amyloidosis. Thus, intratubular amyloid should be systematically screened for in kidney biopsies from patients with light chain cast nephropathy and, if detected, should prompt a work-up for associated systemic light chain amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29052601     DOI: 10.1038/modpathol.2017.124

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  36 in total

1.  Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence.

Authors:  R P Linke
Journal:  Virchows Arch       Date:  2000-05       Impact factor: 4.064

2.  Fluorescent amyloid staining of casts in myeloma nephrosis.

Authors:  P S VASSAR; C F CULLING
Journal:  Arch Pathol       Date:  1962-01

3.  Intralysosomal formation of amyloid fibrils.

Authors:  T Shirahama; A S Cohen
Journal:  Am J Pathol       Date:  1975-10       Impact factor: 4.307

4.  Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

Authors:  Colin A Hutchison; Paul Cockwell; Steven Reid; Katie Chandler; Graham P Mead; John Harrison; John Hattersley; Neil D Evans; Mike J Chappell; Mark Cook; Hermann Goehl; Markus Storr; Arthur R Bradwell
Journal:  J Am Soc Nephrol       Date:  2007-01-17       Impact factor: 10.121

5.  Intra-tubular amyloidosis.

Authors:  Z El-Zoghby; D Lager; J Gregoire; M Lewin; S Sethi
Journal:  Kidney Int       Date:  2007-07-04       Impact factor: 10.612

6.  ESRD due to Multiple Myeloma in the United States, 2001-2010.

Authors:  Scott Reule; Donal J Sexton; Craig A Solid; Shu-Cheng Chen; Robert N Foley
Journal:  J Am Soc Nephrol       Date:  2015-10-29       Impact factor: 10.121

7.  Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.

Authors:  Alexandre Decourt; Bertrand Gondouin; Jean Christophe Delaroziere; Philippe Brunet; Marion Sallée; Stephane Burtey; Bertrand Dussol; Vadim Ivanov; Regis Costello; Cecile Couchoud; Noemie Jourde-Chiche
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-04       Impact factor: 8.237

8.  The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.

Authors:  M A Dimopoulos; M Roussou; M Gkotzamanidou; N Nikitas; E Psimenou; D Mparmparoussi; C Matsouka; M Spyropoulou-Vlachou; E Terpos; E Kastritis
Journal:  Leukemia       Date:  2012-07-05       Impact factor: 11.528

9.  Renal lesions in multiple myeloma: their relationship to associated protein abnormalities.

Authors:  G S Hill; L Morel-Maroger; J P Méry; J C Brouet; F Mignon
Journal:  Am J Kidney Dis       Date:  1983-01       Impact factor: 8.860

10.  In vitro AL-amyloid formation by rat and human mesangial cells.

Authors:  Y M Tagouri; P W Sanders; M M Picken; G P Siegal; J D Kerby; G A Herrera
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

View more
  4 in total

1.  Unusual morphology of amyloid cast nephropathy in renal biopsy portending poor prognosis.

Authors:  Meyyappa Devan Rajagopal; Rajesh Nachiappa Ganesh; Sreejith Parameswaran; Dhanin Puthiyottil
Journal:  BMJ Case Rep       Date:  2018-12-22

2.  The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Authors:  Nelson Leung; Frank Bridoux; Vecihi Batuman; Aristeidis Chaidos; Paul Cockwell; Vivette D D'Agati; Angela Dispenzieri; Fernando C Fervenza; Jean-Paul Fermand; Simon Gibbs; Julian D Gillmore; Guillermo A Herrera; Arnaud Jaccard; Dragan Jevremovic; Efstathios Kastritis; Vishal Kukreti; Robert A Kyle; Helen J Lachmann; Christopher P Larsen; Heinz Ludwig; Glen S Markowitz; Giampaolo Merlini; Peter Mollee; Maria M Picken; Vincent S Rajkumar; Virginie Royal; Paul W Sanders; Sanjeev Sethi; Christopher P Venner; Peter M Voorhees; Ashutosh D Wechalekar; Brendan M Weiss; Samih H Nasr
Journal:  Nat Rev Nephrol       Date:  2019-01       Impact factor: 28.314

Review 3.  Two kinds of rare light chain cast nephropathy caused by multiple myeloma: case reports and literature review.

Authors:  Li-Jun Sun; Hong-Rui Dong; Xiao-Yi Xu; Guo-Qin Wang; Hong Cheng; Yi-Pu Chen
Journal:  BMC Nephrol       Date:  2021-01-28       Impact factor: 2.388

4.  Myeloma cast nephropathy with diffuse amyloid casts without systemic amyloidosis: two cases report.

Authors:  Zi-Hao Yong; Xiao-Juan Yu; Zi-Shan Lin; Fu-de Zhou; Xi-Nan Cen; Su-Xia Wang; Ming-Hui Zhao
Journal:  BMC Nephrol       Date:  2021-01-06       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.